Business Wire

NJ-KOLMAR-KOREA

16.7.2024 15:01:28 CEST | Business Wire | Press release

Share
Kolmar Korea Appoints Global Experts to Speed up Its Presence in North America

Kolmar Korea (KRX: 161890) is speeding up its global expansion by appointing experts in the global cosmetics industry to its North American subsidiary. With the plan to build its second U.S. plant early next year, the company has appointed a new head for its North American operations and a Global Chief Commercial Officer (GCCO). It has also set up a strategic framework that integrates production, sales, and R&D to better penetrate the local market. This plan includes creating an R&D team for North America and appointing a new manager.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716576189/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Kolmar USA 2nd plant (Photo: Kolmar Korea)

Kolmar Korea announced that it has named President Yongchul Hur as CEO of Kolmar Laboratories and Kolmar USA, its North American subsidiaries. Philippe Warnery has been appointed as Global Chief Commercial Officer (GCCO), George Rivera as Chief Science Officer (CSO) of the North American subsidiary, and Managing Director Inki Park as head of the R&D Center for North America, responsible for bridging the Korean and North American markets.

The key part of the recent appointments is bringing in many people with vast experience in the global cosmetics market. This is expected to help the company enter the North American market successfully.

Yongchul Hur, the new CEO of Kolmar North American subsidiaries, brings a wealth of experience in the global ODM business, having overseen production of Kolmar Korea's skincare and makeup products. He has previously served as president of Kolmar Beijing and Kolmar Wuxi, driving significant growth in Kolmar's Chinese operations. Prior to his tenure at Kolmar Korea, he held prominent positions in the cosmetics manufacturing industry, including factory manager at Amore Pacific and CEO of Cosvision. President Hur intends to leverage his decades of industry experience to steer local business in North America.

Philippe Warnery, newly appointed as Global Chief Commercial Officer (GCCO), is an expert in the global cosmetics market. His prior roles include CEO of Intercos North America, an Italian cosmetics ODM, and President of the UK & Ireland Region and General Manager of the Canadian Affiliate at Estee Lauder. With 25 years of experience in the global cosmetics industry, spanning both brand companies and ODM companies, his extensive network is a key competitive advantage. Warnery aims to focus on securing significant sales from major global brands as well as indie brands and recruiting influencers that are gaining popularity worldwide.

George Rivera, appointed as Chief Science Officer (CSO) of Kolmar North American subsidiaries, is an expert with over 20 years of R&D experience at global cosmetics companies such as L'Oreal USA and Intercos. Most recently, he led process and technology innovation as president of Kolmar USA. CSO Rivera, in collaboration with Inki Park, head of the North American R&D Center, plans to concentrate on research and development tailored to the local market's needs.

Center Head Park, a research expert with 18 years of experience, is responsible for adapting core technologies developed at the Kolmar R&D Complex, the Kolmar Group's global R&D hub located in South Korea, to the local market. Utilizing data accumulated at the Complex, including color, formulation, and scent, Park's team will analyze the needs of overseas markets and focus on developing customized formulations.

Kolmar Korea intends to leverage this strategic hires to maximize the operational capacity of its North American production facilities, including the first U.S. plant and the second plant under construction. The company aims to achieve $100 million in sales in the next five years. To this end, it plans to aggressively expand its sales network not only in North America but also in Central and South America. Moreover, with the rising popularity of K-beauty in the U.S. market through global distribution channels such as Amazon, the company plans to actively promote ODM sales that emphasize market accessibility and logistics efficiency for small and medium-sized Korean indie brands seeking entry into the U.S. market.

A representative of Kolmar Korea stated, “This appointment underscores our commitment to gaining new momentum in the North American market by placing industry experts at the forefront. Kolmar Korea will focus on fostering growth through the synergistic collaboration of sales, production, and R&D and expanding its influence beyond North America to Europe."

Understanding the importance of the North American market, Kolmar Korea has acquired Kolmar USA (formerly known as PTP) and Kolmar Canada (formerly known as CSR) in 2016 preemptively establishing a foundation for global expansion. In 2022, Kolmar Korea acquired 100% of the ‘Kolmar’ brand trademark rights, securing exclusive rights to the brand and enabling unrestricted business operations in the U.S. and global markets. The company is expanding its sales network with the recent opening of the Kolmar Innovation Center in New Jersey, USA.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716576189/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release

Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye